biostudies-literaturePolack BANR22https://www.ebi.ac.uk/biostudies/studies/S-EPMC12798002biostudies-literatureUnknown19(1)This study reports a new therapeutic approach for canine giardiasis, the most common intestinal protozoan infection caused by Giardia intestinalis. It is based on the use of the probiotic strain Lactobacillus johnsonii CNCM I-4884 and, in particular, its bile salt hydrolase enzymatic activities. Clinical trials in dogs demonstrated that daily administration of L. johnsonii CNCM I-4884 significantly reduced Giardia cyst shedding after 14 days. These results highlight the potential of this probiotic as a promising alternative to antimicrobials, such as nitroimidazoles or benzimidazoles, for the treatment of giardiasis in dogs. Moreover, they provide a novel approach for the veterinary industry to develop innovative products targeting this parasite. In addition to its direct anti-Giardia effeParasites & vectorsImpact of Lactobacillus johnsonii CNCM I-4884 on canine giardiasis: a probiotic-based approach.PMC12798002This research was funded by prematurity PoC in labs program (Université Paris-Saclay, 2016-2018) and Agence Nationale de la Recherche [ANR-23-CE18-0022].Thomas MWu-Chuang AMammeri MAbuin-Denis LJacouton EBermudez-Humaran LGCabezas-Cruz APolack BFlorent IfalseImpact of Lactobacillus johnsonii CNCM I-4884 on canine giardiasis: a probiotic-based approach.This study reports a new therapeutic approach for canine giardiasis, the most common intestinal protozoan infection caused by Giardia intestinalis. It is based on the use of the probiotic strain Lactobacillus johnsonii CNCM I-4884 and, in particular, its bile salt hydrolase enzymatic activities. Clinical trials in dogs demonstrated that daily administration of L. johnsonii CNCM I-4884 significantly reduced Giardia cyst shedding after 14 days. These results highlight the potential of this probiotic as a promising alternative to antimicrobials, such as nitroimidazoles or benzimidazoles, for the treatment of giardiasis in dogs. Moreover, they provide a novel approach for the veterinary industry to develop innovative products targeting this parasite. In addition to its direct anti-Giardia effe2025-01-01T00:00:00Z2025 Dec2026-06-06T15:22:52.938Z2026-06-01T03:10:57.978ZS-EPMC127980024135343410.1186/s13071-025-07166-3